| Zinbryta (daclizumab) / Biogen, AbbVie |
ACTRN12606000306516: Monotherapy Phase II Dose Ranging Study of DAC HYP in Relapsing Remitting Multiple Sclerosis |
|
|
| Not yet recruiting | 2 | 264 | | | Biogen Idec, Biogen Idec | Multiple Sclerosis | | | | |
NCT00006350: Mycophenolate Mofetil, Tacrolimus, Daclizumab, and Donor Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer |
|
|
| Completed | 2 | | US | daclizumab, therapeutic allogeneic lymphocytes, mycophenolate mofetil, tacrolimus, peripheral blood stem cell transplantation | University of Maryland, Baltimore | Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes | 11/01 | 11/01 | | |
NCT00028288: Study of Daclizumab in Patients With Chronic, Persistent Asthma |
|
|
| Completed | 2 | 120 | US | Daclizumab | Facet Biotech | Asthma | 12/03 | 12/03 | | |
TAST, NCT00693524: Sequential Therapy (FK506 + Monoclonal Anti-IL2R Antibodies + MMF) Versus FK506 With Steroids in Liver TX |
|
|
| Completed | 2 | 94 | Europe | tacrolimus, FK506, Prograf, Anti-IL2R AB, daclizumab, Mycophenolate mofetil, prednisone, steroid | Astellas Pharma Inc | Liver Transplantation | 03/04 | 03/04 | | |
| Completed | 2 | 26 | US | Daclizumab | National Eye Institute (NEI) | Behcet's Syndrome, Retinal Disease, Uveitis | | 06/04 | | |
NCT00043667: Daclizumab Injections to Treat Non-Infectious Sight-Threatening Uveitis |
|
|
| Completed | 2 | 15 | US | Daclizumab | National Eye Institute (NEI) | Uveitis | | 10/04 | | |
NCT00049725: Daclizumab to Treat Chronic Immune Thrombocytopenia |
|
|
| Completed | 2 | 24 | US | Daclizumab | National Institutes of Health Clinical Center (CC) | Thrombocytopenia | | 12/04 | | |
| Completed | 2 | 75 | US | Daclizumab | National Institute of Allergy and Infectious Diseases (NIAID) | Wegener's Granulomatosis | | 05/05 | | |
| Completed | 2 | 36 | US, Canada, Europe | Islet Transplantation, Sirolimus, Tacrolimus, Daclizumab, Sulfamethoxazole, Ganciclovir, Trimethoprim, Pentamidine | National Institute of Allergy and Infectious Diseases (NIAID), Immune Tolerance Network (ITN) | Diabetes Mellitus, Insulin-Dependent | 06/05 | 08/10 | | |
| Completed | 2 | 22 | US | Zenapax | National Institute of Neurological Disorders and Stroke (NINDS) | Multiple Sclerosis | 08/05 | 09/08 | | |
NCT00072969: A Randomized Trial of Recombinant Humanized Anti-IL-2 Receptor Antibody (Daclizumab) Versus Antithymocyte Globulin (ATG) to Treat the Cytopenia of Myelodysplastic Syndrome (MDS) |
|
|
| Completed | 2 | 132 | US | Daclizumab | National Heart, Lung, and Blood Institute (NHLBI) | Myelodysplastic Syndromes | | 08/05 | | |
NCT00073047: Humanized Anti-IL-2 Receptor Monoclonal Antibody in Moderate-to-severe Ulcerative Colitis |
|
|
| Completed | 2 | 150 | US, Canada, Europe | Daclizumab | Facet Biotech | Ulcerative Colitis, Gastrointestinal Disease, Inflammatory Bowel Disease | | 07/06 | | |
| Completed | 2 | 270 | US, Canada | Daclizumab (Anti-CD25 Humanized Monoclonal Antibody) | PDL BioPharma, Inc. | Multiple Sclerosis | | 10/06 | | |
NCT00070759: Daclizumab to Treat Non-Infectious Sight-Threatening Uveitis |
|
|
| Completed | 2 | 6 | US | Daclizumab | National Eye Institute (NEI) | Uveitis | | 10/06 | | |
NCT00326508: Combination Daclizumab/Denileukin Diftitox to Treat Uveitis |
|
|
| Completed | 2 | 5 | US | Daclizumab | National Eye Institute (NEI) | Non-infectious Intermediate and Posterior Uveitis | | 12/06 | | |
NCT00198146: Prevention of Diabetes Progression Trial (PDPT) |
|
|
| Completed | 2 | 40 | US | Zenapax | Indiana University School of Medicine, Pescovitz, Mark D., M.D., Roche Pharma AG, Facet Biotech | Newly Diagnosed With Type 1 Diabetes | 02/07 | 02/07 | | |
NCT00446264: Islet Allotransplantation With Steroid Free Immunosuppression |
|
|
| Completed | 2 | 14 | Europe | islet transplantation, surgical catheterisation, percutaneous catheterisation, daclizumab - sirolimus - tacrolimus, Prograf, Rapamune, Zenapax | University Hospital, Lille, Institut National de la Santé Et de la Recherche Médicale, France | Type 1 Diabetes, Hypoglycemia, Metabolic Diseases | 10/07 | 02/09 | | |
NCT00071838: Zenapax (Daclizumab) to Treat Relapsing Remitting Multiple Sclerosis |
|
|
| Completed | 2 | 16 | US | Daclizumab | National Institute of Neurological Disorders and Stroke (NINDS) | Multiple Sclerosis, Relapsing-Remitting | 10/07 | 08/11 | | |
NCT00064714: Effect of AC2993 With or Without Immunosuppression on Beta Cell Function in Patients With Type I Diabetes |
|
|
| Completed | 2 | 47 | US | AC2993 (exenatide), daclizumab (immunosuppressive) | AstraZeneca, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Diabetes Mellitus | 03/08 | 03/08 | | |
NCT00100178: New Onset of Type 1 Diabetes Mycophenolate Mofetil-Daclizumab Clinical Trial |
|
|
| Completed | 2 | 126 | Canada, US | Mycophenolate mofeteil (MMF), Daclizumab (DZB), Placebo control for Mycophenolate mofeteil (MMF), Placebo control for Daclizumab (DZB) | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute of Allergy and Infectious Diseases (NIAID), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), Juvenile Diabetes Research Foundation, National Center for Research Resources (NCRR) | Diabetes Mellitus, Type 1 | 04/08 | 04/08 | | |
NCT00130637: Human Anti-Tac (Daclizumab) to Treat Juvenile Idiopathic Arthritis (JIA)-Associated Uveitis |
|
|
| Completed | 2 | 6 | US | Daclizumab, Human Anti-Tac | National Eye Institute (NEI), The Emmes Company, LLC | Anterior Uveitis, Arthritis, Juvenile Idiopathic, Iritis, Immunosuppression | 05/08 | 05/08 | | |
NCT00001962: A Study to Determine Whether Therapy With Daclizumab Will Benefit Patients With Bone Marrow Failure |
|
|
| Terminated | 2 | 100 | US | Daclizumab, Zenapax | National Heart, Lung, and Blood Institute (NHLBI) | Aplastic Anemia, Pure Red Cell Aplasia, Diamond Blackfan Anemia | 08/09 | 09/10 | | |
NCT00790439: Safety and Effectiveness of Low Molecular Weight Sulfated Dextran in Islet Transplantation After Kidney Transplant |
|
|
| Withdrawn | 2 | 0 | US | Low Molecular Weight Sulfated Dextran, LMW-SD, Heparin, Heparin Sodium, Mycophenolate Mofetil, MMF, Mycophenolate, Mycophenolic Acid, CellCept, Sirolimus, Rapamune, Tacrolimus, Hecoria, Cyclosporine, Ciclosporin, GENGRAF® Capsules, Daclizumab, Basiliximab, Simulect ®, Allogeneic Pancreatic Islet Cells | National Institute of Allergy and Infectious Diseases (NIAID), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Diabetes Mellitus, Type I | 10/09 | 10/09 | | |
AMDB1, NCT00304954: Infliximab, Sirolimus and Daclizumab to Treat Age-Related Macular Degeneration |
|
|
| Completed | 2 | 13 | US | Intravenous Daclizumab, Zenapax, Intravenous Infliximab, Remicade, Observation, Oral Rapamycin, Sirolimus | National Eye Institute (NEI) | Age-Related Macular Degeneration, Choroidal Neovascularization | 01/10 | 01/10 | | |
| Completed | 2 | 621 | Europe, RoW | BIIB019 (Daclizumab High Yield Process), DAC HYP, Daclizumab HYP, Placebo | Biogen, AbbVie | Relapsing-Remitting Multiple Sclerosis | 05/11 | 08/11 | | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
NCT00434850: Peritransplant Deoxyspergualin in Islet Transplantation in Type 1 Diabetes |
|
|
| Completed | 2 | 14 | US | Allogeneic Pancreatic Islet Cells, Deoxyspergualin, Antithymocyte globulin, Daclizumab or basiliximab, Sirolimus, Tacrolimus, Etanercept | National Institute of Allergy and Infectious Diseases (NIAID), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Diabetes Mellitus, Type 1 | 09/11 | 11/13 | | |
NCT00468442: B-Lymphocyte Immunotherapy in Islet Transplantation |
|
|
| Terminated | 2 | 2 | US | Allogeneic Pancreatic Islet Cells, Antithymocyte globulin, ATG, Daclizumab, Zenapax, Rituximab, Rituxan, Sirolimus, Rapamune | National Institute of Allergy and Infectious Diseases (NIAID), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Type 1 Diabetes Mellitus | 09/11 | 09/11 | | |
SELECTION, NCT00870740 / 2008-005559-46: Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) in Participants With Multiple Sclerosis Who Have Completed Study 205MS201 (NCT00390221) to Treat Relapsing-Remitting Multiple Sclerosis |
|
|
| Completed | 2 | 517 | Europe, RoW | BIIB019 (Daclizumab High Yield Process), Daclizumab HYP, DAC HYP, Placebo | Biogen, AbbVie | Relapsing-Remitting Multiple Sclerosis | 05/12 | 10/12 | | |
|
|
|
|
|
|
|
NCT01307618: Vaccine Therapy With or Without Recombinant Interleukin-12 Followed by Daclizumab in Treating Patients With Metastatic Melanoma |
|
|
| Terminated | 2 | 10 | US | NA17.A2 Peptide Vaccine, NA17.A2, Recombinant MAGE-3.1 Antigen, MAGE-3, MAGE-3.1, Recombinant Interleukin-12, MART-1 Antigen, Antigen LB39-AA, Antigen SK29-AA, MART-1 Tumor Antigen, Laboratory Biomarker Analysis | National Cancer Institute (NCI) | Recurrent Melanoma, Stage IV Skin Melanoma | 01/15 | 02/15 | | |
SELECTED, NCT01051349 / 2009-015318-23: Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) (BIIB019) in Participants Who Have Completed Study 205MS202 (NCT00870740) to Treat Relapsing Remitting Multiple Sclerosis |
|
|
| Completed | 2 | 410 | Europe, RoW | BIIB019 (Daclizumab), Daclizumab High Yield Process, DAC HYP, trivalent seasonal influenza vaccine | Biogen, AbbVie | Relapsing-Remitting Multiple Sclerosis | 08/16 | 08/16 | | |
|
|
|
|
NCT00002681: Monoclonal Antibody Plus Interleukin-2 in Treating Patients With Leukemia or Lymphoma |
|
|
| Completed | 1/2 | 25 | US | aldesleukin, daclizumab | Roger Williams Medical Center, National Cancer Institute (NCI), Beth Israel Deaconess Medical Center | Leukemia, Lymphoma | 09/03 | 12/03 | | |
NCT00050661: To Study the Use of Humanized CD25 in Preventing the Relapse of Psoriasis Vulgaris |
|
|
| Completed | 1/2 | 6 | US | Daclizumab, anti-TAC, NB-UVB | Rockefeller University, Facet Biotech | Psoriasis | 04/04 | 04/08 | | |
NCT00050648: To Study the Effects of CD25 and Low Dose Cyclosporin in the Treatment of Active Psoriasis Vulgaris |
|
|
| Completed | 1/2 | 20 | US | Daclizumab, Cyclosporine, Neoral, cyclosporine and Daclizumab | Rockefeller University, Facet Biotech | Psoriasis | 09/04 | 04/08 | | |
NCT00285233: Delayed Mycophenolate Mofetil in Single-Donor Islet Allotransplantation in Type 1 Diabetes |
|
|
| Completed | 1/2 | 8 | US | Allogeneic islets of Langerhans transplant, Islet transplant | University of Minnesota, Roche Pharma AG, Juvenile Diabetes Research Foundation | Type 1 Diabetes, Hypoglycemia | 09/04 | 03/05 | | |
NCT00847106: Augmentation of Dendritic Cell-Based Vaccines in Melanoma Patients by Depletion of Regulatory T Cells in Stage IV Melanoma Patients |
|
|
| Completed | 1/2 | 15 | Europe | Daclizumab, Dendritic cells | Radboud University Medical Center, Dutch Cancer Society | Melanoma | 10/05 | 10/05 | | |
NCT00019227: Monoclonal Antibody Therapy in Treating Patients With Leukemia |
|
|
| Completed | 1/2 | | US | pentetic acid calcium, yttrium Y 90 daclizumab | National Cancer Institute (NCI) | Lymphoma, Radiation Toxicity | | 07/06 | | |
NCT00141037: Steroid-Free Versus Steroid-Based Immunosuppression in Pediatric Renal (Kidney) Transplantation |
|
|
| Completed | 1/2 | 130 | US | Daclizumab, ZENAPAX®, Humanised Anti-Tac Antibody, Ro-24-7375, Mycophenolate mofetil (MMF), CellCept®, Prednisone, Tacrolimus, Prograf®, Ganciclovir, Cytovene, Valganciclovir, Valcyte, Trimethoprim and sulfamethoxazole, Septra®) | National Institute of Allergy and Infectious Diseases (NIAID), Astellas Pharma Inc, Hoffmann-La Roche | Kidney Diseases, Kidney Transplantation, Kidney Transplant, Renal Transplantation, Renal Transplant | 09/06 | 11/10 | | |
NCT00284531: Use of Daclizumab for the Prevention of Allograft Rejection in Pediatric Heart Transplant Patients |
|
|
| Terminated | 1/2 | 1 | US | Daclizumab | Baylor College of Medicine, Roche Pharma AG | Cardiac Transplantation | 05/07 | 05/07 | | |
| Completed | 1/2 | 34 | US | daclizumab, Zenapax | National Cancer Institute (NCI) | HTLV-I Infection, T Cell Leukemia | 02/11 | 02/11 | | |
NCT00579527: Phase I/II Thymus Transplantation With Immunosuppression #950 |
|
|
| Completed | 1/2 | 14 | US | Cultured Thymus Tissue for Implantation (CTTI), Thymus Tissue Transplant, CTTI, Cultured Thymus Tissue Implantation and Parental Parathyroid Transplantation, Thymus and Parathyroid Transplant, CTTI and Parathyroid Transplant, Blood Draw, Venipuncture, Rabbit anti-thymocyte globulin, RATGAM, thymoglobulin, Cyclosporine, Csa, Tacrolimus, FK506, Methylprednisolone or Prednisolone, Steroids, Daclizumab, Zenapax, Mycophenolate mofetil, MMF, CellCept | Enzyvant Therapeutics GmBH, National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | DiGeorge Anomaly, Complete DiGeorge Anomaly, Complete Atypical DiGeorge Anomaly, Complete DiGeorge Syndrome, Complete Atypical DiGeorge Syndrome | 12/11 | 12/17 | | |
NCT01468311: Yttrium-90-labeled Daclizumab With Chemotherapy and Stem Cell Transplant for Hodgkin's Lymphoma |
|
|
| Terminated | 1/2 | 6 | US | Auto stem cell transplant, BEAM, 111In-daclizumab, 90Y-daclizumab | National Cancer Institute (NCI) | Hodgkin Disease, Hodgkin Lymphoma | 11/14 | 10/20 | | |
